Elevance Health Shares Rise 5% on Strong Q2 Revenue Growth

Elevance Health's stock experienced a 5.1% surge in pre-market trading driven by bullish technical indicators and strong insider and institutional investor confidence, despite recent challenges from elevated medical costs in government-backed plans and a lowered annual profit forecast. The company reported Q2 2025 adjusted EPS of $8.84, slightly missing expectations, with medical cost trends and slower Medicaid rate recovery impacting margins, but revenue increased 14% year-over-year to $49.4 billion. Membership declined to 45.6 million due to decreases in Medicaid and ACA enrollment, prompting Elevance Health to reduce its full-year EPS guidance to $30, while maintaining strategic initiatives focused on AI-enabled care management and value-based services through Carelon. Analysts remain optimistic, with Mizuho maintaining a 'Buy' rating and $342 price target based on growth potential and Medicare Advantage execution. Separately, Elah Holdings released its unaudited Q2 2025 financial statements, emphasizing its focus on acquiring profitable commercial and industrial businesses to enhance long-term shareholder value. ELUTIA reported a quarterly loss and missed revenue estimates, yet attracted mixed institutional investment activity and holds a median analyst price target of $8.00, reflecting cautious market sentiment.